Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Review
Nature Reviews Drug Discovery 4, 236–248 (1 March 2005) | doi:10.1038/nrd1660
Integrase inhibitors to treat HIV/Aids
&
Abstract
HIV integrase is a rational target for treating HIV infection and preventing AIDS. It took approximately 12 years to develop clinically usable inhibitors of integrase, and Phase I clinical trials of integrase inhibitors have just begun. This review focuses on the molecular basis and rationale for developing integrase inhibitors. The main classes of lead compounds are also described, as well as the concept of interfacial inhibitors of protein–nucleic-acid interactions that might apply to the clinically used strand-transfer inhibitors.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
